▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #745 by analyst upside · 2026-09-27
NUVB
Nuvation Bio Inc.
Healthcare · Market Cap $2B · P/E 0x
ANALYST PRICE TARGET
+128.2%
implied upside to consensus target
Current Price $5.74
Consensus Target $13.1
Bull Target $21.0
Bear Target $7.0
Analysts Covering 10
ANALYST CONSENSUS - BUY
Strong Buy
3
Buy
6
Hold
1
Sell
0
52-Week Low $3.15
52-Week High $9.75
YTD Return -33.1%
FUNDAMENTALS
Market Cap $2B
P/E Ratio (TTM) N/A
Forward P/E N/A
EPS (TTM) $-0.44
PEG Ratio N/A
Dividend Yield N/A
Revenue (TTM) $170M
Profit Margin -88.2%
52-WEEK RANGE
52-Week Low $3.15
52-Week High $9.75
Current Price $5.74
Bear Target $7.0
Bull Target $21.0
● Now $5.74 ● Target $13.1
TRADING DATA
Avg Volume 5.9M
YTD Return -33.1%
Analyst Count 10
Consensus Buy
Upside to Target +128.2%
Last Updated 2026-09-27

ANALYST SUMMARY

Nuvation Bio Inc. (NUVB) is currently trading at $5.74 with a Wall Street consensus price target of $13.1, implying potential upside of 128.2% over the next 12 months. 10 analysts currently cover NUVB, with a consensus rating of Buy - 90% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $21.0, while the most cautious has a target of $7.0.

NUVB operates in the Healthcare sector with a market capitalisation of $2B. The stock is down 33.1% year-to-date and is currently trading near the lower end of its 52-week range of $3.15 – $9.75.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

GTBIF +106.5%
Green Thumb Industries Inc.
$2B · P/E 14.4x · Buy
ADMA +81.2%
ADMA Biologics, Inc.
$2B · P/E 13.4x · Buy
INVA +68.8%
Innoviva, Inc.
$1B · P/E 4.8x · Buy
PBH +45.5%
Prestige Consumer Healthcare Inc.
$2B · P/E 13.1x · Buy
VOR +110.6%
Vor Biopharma Inc.
$1B · P/E 0.1x · Buy

RECENT ANALYST CALLS

Upgrade/downgrade history for NUVB, with each firm's 90-day track record across all stocks we track. See full firm rankings →

Citizens reit
Market Outperform → Market Outperform 2026-09-16 Building track record
Wedbush reit
Outperform → Outperform 2026-09-16 Building track record
Cantor Fitzgerald ● Initiated
Overweight 2026-08-21 40% win rate (10 calls)
JP Morgan ● Initiated
Overweight 2026-08-18 43% win rate (7 calls)
RBC Capital - Reiterated
Outperform → Outperform 2026-08-07 Building track record
HC Wainwright & Co. - Reiterated
Buy → Buy 2026-07-27 31% win rate (48 calls)
Wedbush reit
Outperform → Outperform 2026-07-23 Building track record
RBC Capital - Reiterated
Outperform → Outperform 2026-07-07 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
40
out of 100
Coverage depth
18/30
Consensus clarity
0/30
Vote unanimity
20/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →